

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop PCT/Sequence, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313 on:

May 9, 2007

David Saliwanchik

David R. Saliwanchik, Patent Attorney

AMENDMENT UNDER
37 CFR 1.825(a) THROUGH (c)
Patent Application
Docket No. SPO-127

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hiroshi Tsuboi *et al.*
Serial No. : 10/578,015
Filed : May 3, 2006
Conf. No. : 6720
For : Plant-Derived Beta3-Adrenergic Receptor Agonist Substances and Uses
Thereof

Mail Stop PCT/Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF:
SEQUENCE LISTING UNDER 37 CFR §1.821 &
AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements regarding the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows: